Martin Borch Jensen Profile picture
Sep 1, 2020 24 tweets 11 min read Read on X
Livetweets from the 7th Annual Aging Research and Drug Discovery conference #ARDD2020. I can't attend every talk to coverage will be intermittent. Apologies to any speakers left out!
Christian Riedel from @karolinskainst presenting aging clocks. There are a lot of these, but excited to see him (A) making a human clock predicting time to death, not just age, and (B) deconvoluting both their human and model org clocks into FUNCTIONAL parameters. Sorely needed.
Now haut.ai from Estonia arguing that hand photos are more robust than faces for AI-based aging biomarkers, and that we need more explicit skin tone features for broadly applicable tools.
PS, Estonia is probably the world leader in digital health/EHRs.
@aubreydegrey from @agexthera commenting on @UnityBiotech's recent OA clinical trial results: "Clinical trials are experiments, and they often fail. That's normal, not a reason to lose hope in aging therapeutics".
And on #COVID19: Anti-aging for a less vulnerable population.
Gordian coming up after a short break! (No company twitter account, yet).
Polina Mamoshima talking about issues with AI-based aging clocks from blood samples: Specific contributing features don't map uniquely to biological aging, and clocks have large errors when applied to different genetic backgrounds than they're trained on. And yet there's signal.
Steve Horvath talking about a targeted array for scalable #Epigenetic clock measurements in mice. Disease models show accelerated aging (Huntington only weakly), CR or growth hormone KO slowed aging. Rapamycin only weak effect.
He has also made clocks that are compatible with human+elephant, human+cat, human+dog pairs😲
@ScheibyeKnudsen presenting a (secret) drug reducing #Senescence, determined by computer vision tracking cell culture senescence and drosophila movement with age. Supposed to boost #DNArepair, although I missed if he presented data for this.
back in my PhD days the mantra was that boosting DNA repair hadn't been successful for boosting lifespan, because toxic intermediates (e.g. strand breaks) mean that you'd have to boost the whole pathway while also keeping it in perfect equilibrium. Curious how this new drug works
Peter de Keizer arguing that 'senescence' is not a single phenotype across cell types😲. And some common senescence markers don't work at the single-cell level. He's making different cells from same iPS and inducing senescence, to determine cell type specific features.❤️
Why is he crushing our reductionist dreams, disrupting thehappy coexistence when we pretend that all #Senescence is the same?! Obviously because his company clearabiotech.com needs to figure out which diseases it can cure by targeting different senescence cells.
Debra Toiber from Ben Gurion U studying Sirt6 in DNA damage response: Independently recruited to DSBs within 5s, and recruits canonical HR & NHEJ proteins. Sirt6KO -> increase in p-tau, resembles tau174acetylation phenotype, increases nucleolus size/translation. Very interesting!
The excellent Tom Rando rounds out the day, talking about cycling D1 as an exercise-induced regeneration factor, seemingly transferable through #parabiosis. Paper: nature.com/articles/s4225…
@pak_heidi from @LammingLab did a great study decoupling #CaloricRestriction and #Fasting. For the uninitiated, CR in lab animals is normally achieved by once-daily feeding of a fixed amount, for practical reasons. The animals will eat all the food immediately and de facto fast.
Heidi used diluted and enriched food to achieve CR without fasting, and found that metabolic shifts in liver and muscle, and life extension, only occurred with a fast period! @KarlPfleger we've discussed whether fasting is as good as CR, but maybe it's the other way around :)
Rafa de Cabo presented pretty dramatic data on using disulfiram (commonly used to treat alcoholism by making you throw up when you drink) to increase autophagy and counteract the effects of high-fat diets.
The divide between bodybuilders and aging biologists widens, with @LammingLab data from old, young, & accel. aging mice: variable but mostly better health when limiting branched-chain amino acids in isocaloric diets.

(PS not implying Dudley Lamming is not a bodybuilder😇)
Between this, the recent @BuckInstitute paper on alpha-ketoglutarate (cell.com/cell-metabolis…), mouse to human translation and everything else, I think it's safe to say that macronutrients diets and longevity is still up in the air.
Alice Kane from @davidasinclair lab presented a random forest-based tool to score mouse frailty and est. time to death, based on a frailty index mirroring human clinical frailty: frailtyclocks.sinclairlab.org. Looks like a cool effort to help standardize aging mouse data.
Finally, @davidasinclair talks about my favorite #Aging topic: epigenetic loss of identity. Mostly this opus preprint: biorxiv.org/content/10.110…, where they used AAV to deliver OSK (no M) to old mouse eyes. RGC cells that receive cargo are protected from nerve crush/glaucoma model
New data: They see a reset of DNA methylation aging clocks with treatment. Adding shRNAs against Tet1 or 2 they lose the signal. Changing methylation sites were enriched for PRC2 targets. Repeating work in cerebral neurons.
Thanks for organizing this conference @ScheibyeKnudsen and @biogerontology! #ARDD2020
Side note: It was cool to see the new @NatureAging in the audience, and hear a new aging-focused @FrontiersIn
journal announced. More #Aging journals will be a great outlet both for studies of the fundamental biology, and (I hope) for linking basic biology to #AgeRelatedDisease.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Martin Borch Jensen

Martin Borch Jensen Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MartinBJensen

Mar 31
I'm struggling to wrap my head around the new Weissman lab myHSC depletion paper:
The first authors don't seem to be on twitter but hoping I can crowdsource a fun discussion. @dbgoodman @ImmunoFever @Jeff_Mold @Satpathology @CalebLareau...nature.com/articles/s4158…
The premise of the paper is that immune function declines with age in part because a haematopoetic stem cell (HSC) population skewed towards myeloid lineage increases in prevalence, and that targeting this population with antibodies can restore function. Cool idea!
❓1⃣: How well defined are myHSCs?
Here myHSC seems to be defined as CD150 high, based mainly on Beerman 2010 .
But looking at Figure 3, CD150 expression is a continuous distribution. Is this a clear cell population with somewhat understood behavior? pnas.org/doi/full/10.10…
Image
Read 11 tweets
Jul 5, 2022
If you want to build a career in biotech, should you get a PhD after college or join a company directly (as a Research Associate/RA, usually)?
There's no single answer, but I have the conversation often enough that I thought I'd share some pros/cons... (1/n)
First, see this thread about different types of biopharma companies. For reasons I'll get into, I think early stage (probably founder led) biotech is your best bet unless you still want to do PhD later.
(PS if you want to be a professor, it's 💯 PhD) 2/n
PhD will give you more options.
Some companies (incl. @GordianBio) will help you grow from RA to Scientist role (and beyond). But many, esp larger, companies have a glass ceiling if you don't have a PhD. Even if you pick one w/o glass ceiling, you'll be worse off it if fails. 3/n
Read 13 tweets
Jul 3, 2022
All these points resonate, for early stage biotech at least. @erlichya touches on this, but I think worth separating "industry" into different clusters that will feel quite different to someone coming from academia (still oversimplified, of course):
Pharma (eg Pfizer) vs biotech:
You wear fewer hats, see less of the company but company as a whole spans wider range of expertise, fewer changes in direction, often higher income but no chance of getting rich. Both have job insecurity: pharma doesn't go die but programs do.
Clinical vs R&D stage biotech:
Clinical may still have R&D but it's no longer the biggest driver of success vs failure. Assay validation/rigor > assay development/invention. Clinical can feel more like pharma, but with more urgency/stakes: one program = life or death of co.
Read 7 tweets
Jan 24, 2022
#SciTwitter After a lot of research and asking around, I'm making the lab equipment recommendations 🧵 I wish I'd had 2 months ago. RT/share with a #newPI or startup 🔬⚗️🛒
Note, much of the equipment hasn't arrived yet, will add comments after actual use.
-80 #freezer
Two clear winners: PHC (@panasonic) and Stirling Ultracold. Both low energy, quiet, reliable. We went with PHC because I know those to last many years, and slightly cheaper.
Thanks @MarcoJost_ @letUbeU @aryelipman #MBCBiolabs
-20 #freezer
Less clear, many viable options. We ended up getting a split of PHC MDF -30 (recommended as quieter) and much cheaper Corepoint Scientific/@VWR, will see which we prefer. Thermo hasn't failed #MBCbiolabs, but $$$ and several people said poor customer support.
Read 14 tweets
Jan 5, 2022
Something is changing about how scientific research is funded.

@Jasonmmast @endpts covers a growing set of science funding experiments: endpts.com/inside-the-mul…
These include high-throughput grants (e.g. #Fast, #Impetus), new institutes (@ArcadiaScience, @AltosLabs, @arcinstitute... I guess A is for new beginnings?), and new structures like 'nonprofit startups' (@Convergent_FROs) & @newscienceorg.
As with all experiments, I expect that some of these will disappear and that others will be a central part of science in ten years.
But them happening at all is enough to renew a conversation about how science is funded and conducted.
Read 9 tweets
Dec 27, 2021
💸 98 Longevity Impetus Grants were awarded in 2021, thanks to generous donations from @juanbenet @jamesfickel @VitalikButerin @JedMcCaleb @KarlPfleger @FEhrsam and 1 anonymous donor.
I'll summarize outcomes in this thread, awardees listed in prior one:
🦸🏽 While I've been doing most of the tweeting, the Longevity Apprentices @LNuzhna @kush__sharma @edmarferreira & Tara Mei are the real heroes for running the operations.
This has been a great Apprenticeship project, merging action and exposure to research
martinborchjensen.com/apprenticeship
🚅 The review + awards process was fairly smooth, thanks in part to @kush__sharma's custom reviewer UI. Several reviewers told us unprompted that it was their best review experience ever; the UI took 2 wks to make, so there's low hanging fruit for other agencies in that area.
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(